Go to the list of all blogs
Sergey Savastiouk's Avatar
published in Blogs
Nov 17, 2026
TickeronGET DAILY SIGNALS
Rhythm Pharmaceuticals (RYTM) and the Path to a $150 Price Target

Rhythm Pharmaceuticals (RYTM) and the Path to a $150 Price Target

Key Takeaways

  • The central $150 target is the arithmetic mean of the seven most recent, individually attributed analyst price targets, which range from $142 to $168 and average roughly $152.
  • With shares trading near $114, reaching $150 implies a roughly 32% advance, a substantial move that would take the stock above its 52-week high.
  • Broader aggregator estimates that also include older, unrevised targets point to a consensus closer to $140 (S&P Global, 19 analysts, range $112 to $168).
  • Bullish drivers include accelerating IMCIVREE revenue, an expanding rare-obesity franchise, and a Phase 2 pipeline asset (RM-718) that has generated early positive data.
  • Key risks are persistent GAAP losses, negative cash flow, patient-diagnosis barriers, and tolerability questions around RM-718.
  • For more context on this ticker's Major News, Today's Price Move, Forecast, and Earnings, explore these dedicated pages.
  • Readers can also explore Trending AI Robots for automated, AI-driven trading strategies.

Analyst Price Targets and Consensus View

Rhythm Pharmaceuticals, Inc. (RYTM), a Boston-based commercial-stage biopharmaceutical company focused on rare genetic diseases of obesity, carries a near-unanimously bullish sell-side view. For this analysis, the central target is derived from the seven most recent, individually attributed analyst targets published after the company's third-quarter report in early November 2026. Those targets are: Canaccord Genuity's Whitney Ijem at $168, Citizens' Jonathan Wolleben at $166, Wells Fargo at $155, Guggenheim's Seamus Fernandez at $147, Morgan Stanley's Michael Ulz at $146, Citi's Samantha Semenkow at $143, and JPMorgan's Priyanka Grover at $142.

These seven range from $142 to $168 and average approximately $152, which rounds to a $150 central target. For context, independent aggregators that fold in targets not recently revised report a lower consensus near $140 (S&P Global, 19 analysts, range $112 to $168; FactSet, 18 analysts, near $142). The wide spread reflects genuine disagreement: some analysts weight the near-term commercial ramp of the lead drug, while others discount further out for pipeline and cash-burn uncertainty. The $150 figure here is a calculated mean, not an official published consensus. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.

Current Market Position and Path Toward the Target

Shares recently traded near $114, giving Rhythm a market capitalization of roughly $7.9 billion. Reaching $150 would require a gain of about 32% from current levels — a substantial move that would push the stock decisively through its 52-week high of $122.20. The path depends heavily on execution rather than valuation expansion: the company is not yet profitable on a GAAP (generally accepted accounting principles) basis, so investors are paying for future growth of IMCIVREE and the broader melanocortin-4 receptor (MC4R) franchise.

Trailing-twelve-month revenue is about $281 million, and the business has been growing quickly as IMCIVREE (setmelanotide) expands into acquired hypothalamic obesity and additional geographies. Sequential product sales rose roughly 19% in the most recent quarter, supporting the view that commercial traction is broadening beyond initial prescriptions into recurring reimbursed demand.

What Could Support a Move Toward the Target

  • Commercial momentum: IMCIVREE revenue growth, gross margins near 89–91%, and rising reimbursed-patient counts provide strong product-level economics.
  • Expanding label and geography: The acquired hypothalamic obesity launch and planned entries into Japan and Europe diversify the revenue base.
  • Pipeline optionality: RM-718, a next-generation MC4R agonist, showed early efficacy comparable to existing agents, with data covered in the New England Journal of Medicine.
  • Analyst revisions: Several firms raised targets after the November earnings report, reflecting increased confidence in the commercial outlook.

What Could Prevent the Target From Being Reached

  • Persistent losses: Continued GAAP net losses and negative free cash flow keep the company dependent on its roughly $321 million cash balance and could raise dilution risk.
  • Diagnosis and access barriers: Patients must be identified and routed through specialty care, which can slow conversion of the addressable market into reimbursed demand.
  • RM-718 tolerability: Nausea, injection-site reactions, and some early discontinuations create uncertainty around adherence and the eventual commercial profile.
  • Valuation sensitivity: With no meaningful current earnings, the shares are vulnerable to multiple compression if growth disappoints or interest rates rise.

Technical Levels and Market Structure

The stock's 52-week range spans $74.50 to $122.20. The $122 area marks a key resistance zone and prior high that would need to be cleared for any move toward $150. On the downside, recent trading established support in the $103–$105 zone, with a secondary shelf near the $112–$115 region. A decisive breakout above $122, ideally on volume, would be a meaningful technical confirmation, while a slide below $103 could signal renewed selling pressure.

Time Horizon and What Investors Should Monitor

Most analyst price targets reflect a roughly 12-month research horizon, though individual methodologies differ. Upcoming items most relevant to the target include quarterly earnings and guidance, IMCIVREE prescription and reimbursement trends, updates on RM-718 tolerability and development, and progress on international launches. Regulatory decisions, payer coverage changes, and any financing announcements also matter given the company's cash-burn profile. Investors should watch for analyst target revisions as a signal of shifting sentiment rather than as a forecast of a specific price.

Using AI Daily Buy/Sell Signals for Additional Perspective

I often turn to Tickeron’s AI Daily Buy/Sell Signals as a quick way to layer data-driven insights onto fundamental research. These signals scan thousands of stocks and ETFs in real time, highlighting potential shifts based on technical patterns and market conditions. For names like RYTM that sit in a high-growth but unprofitable sector, they can help flag momentum changes that might not be immediately obvious from earnings releases alone. This approach keeps the analysis grounded without replacing traditional due diligence.

Final Assessment

The question of whether RYTM can reach $150 hinges on sustained commercial execution rather than a single catalyst. The target, an average of seven recent analyst views spanning $142 to $168, sits about 32% above the current price and above the broader ~$140 consensus that includes older targets. Support comes from accelerating IMCIVREE revenue, label and geographic expansion, and encouraging RM-718 data. The principal obstacles are ongoing losses, cash-burn and dilution risk, slow patient diagnosis, and RM-718 tolerability. Because the stock is unprofitable, its value rests on growth expectations that can shift quickly with each earnings report and pipeline update. No outcome is guaranteed, and the wide target range underscores genuine disagreement about how quickly the rare-obesity opportunity converts into durable profits.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations

Related Ticker: RYTM

Contributor

Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.


RYTM in upward trend: 10-day moving average crossed above 50-day moving average on November 06, 2026

The 10-day moving average for RYTM crossed bullishly above the 50-day moving average on November 06, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 15 of 16 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 90%.

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The Momentum Indicator moved above the 0 level on November 04, 2026. You may want to consider a long position or call options on RYTM as a result. In 62 of 75 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 83%.

The Moving Average Convergence Divergence (MACD) for RYTM just turned positive on October 20, 2026. Looking at past instances where RYTM's MACD turned positive, the stock continued to rise in 36 of 46 cases over the following month. The odds of a continued upward trend are 78%.

RYTM moved above its 50-day moving average on November 04, 2026 date and that indicates a change from a downward trend to an upward trend.

Following a +1.49% 3-day Advance, the price is estimated to grow further. Considering data from situations where RYTM advanced for three days, in 236 of 293 cases, the price rose further within the following month. The odds of a continued upward trend are 81%.

Bearish Trend Analysis

The 10-day RSI Indicator for RYTM moved out of overbought territory on November 11, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 30 similar instances where the indicator moved out of overbought territory. In 24 of the 30 cases, the stock moved lower in the following days. This puts the odds of a move lower at 80%.

The Stochastic Oscillator demonstrated that the ticker has stayed in the overbought zone for 8 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.

The 50-day moving average for RYTM moved below the 200-day moving average on November 02, 2026. This could be a long-term bearish signal for the stock as the stock shifts to an downward trend.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where RYTM declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 74%.

RYTM broke above its upper Bollinger Band on November 06, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

The Aroon Indicator for RYTM entered a downward trend on October 23, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Fundamental Analysis (Ratings)

The Tickeron Profit vs. Risk Rating rating for this company is 11 (best 1 - 100 worst), indicating low risk on high returns. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock better than average.

The Tickeron Price Growth Rating for this company is 40 (best 1 - 100 worst), indicating steady price growth. RYTM’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Seasonality Score of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.

The Tickeron PE Growth Rating for this company is 57 (best 1 - 100 worst), pointing to average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Valuation Rating of 92 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: RYTM's P/B Ratio (75.068) is slightly higher than the industry average of (3.592). P/E Ratio (-35.987) is within average values for comparable stocks, (-1.190). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (131.305) among similar stocks. P/S Ratio (27.548) is also within normal values, averaging (442.120).

The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

Notable companies

The most notable companies in this group are Moderna (NASDAQ:MRNA), Regeneron Pharmaceuticals (NASDAQ:REGN), Incyte Corp (NASDAQ:INCY), Exelixis (NASDAQ:EXEL), Arrowhead Pharmaceuticals (NASDAQ:ARWR), Sarepta Therapeutics (NASDAQ:SRPT), Novavax (NASDAQ:NVAX), Nektar Therapeutics (NASDAQ:NKTR), Inovio Pharmaceuticals (NASDAQ:INO), Cel-Sci Corp (ASE:CVM).

Industry description

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

Market Cap

The average market capitalization across the Biotechnology Industry is 2.24B. The market cap for tickers in the group ranges from 58 to 138.67B. VRTX holds the highest valuation in this group at 138.67B. The lowest valued company is SEELQ at 58.

High and low price notable news

The average weekly price growth across all stocks in the Biotechnology Industry was -11%. For the same Industry, the average monthly price growth was -10%, and the average quarterly price growth was -24%. SLS experienced the highest price growth at 129%, while CUE experienced the biggest fall at -85%.

Volume

The average weekly volume growth across all stocks in the Biotechnology Industry was 8%. For the same stocks of the Industry, the average monthly volume growth was 10% and the average quarterly volume growth was -15%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 50
P/E Growth Rating: 44
Price Growth Rating: 67
SMR Rating: 93
Profit Risk Rating: 93
Seasonality Score: -3 (-100 ... +100)
AI Screener 4
View a ticker or compare two or three
Interact to see
Advertisement
A.I.Advisor
published price charts
A.I. Advisor
published General Information

General Information

a developer of peptide therapeutics for metabolic diseases

Industry Biotechnology

Industry
Biotechnology
Address
222 Berkeley Street
Phone
+1 857 264-4280
Employees
414
Web
https://www.rhythmtx.com
Interact to see
Advertisement
UNH dropped -7.80% to $359.29 from Tuesday's $389.68 close, extending a two-session decline to roughly -13% and touching its lowest level in about seven weeks; the move occurred during regular market hours. The selloff accelerated on the CMS "CRUSH" proposal unveiled Nov. 16, which would extrapolate Medicare Advantage risk-adjustment audit findings from samples across entire contracts back to payment year 2018 and drop the fee-for-service adjuster; CMS estimates roughly $9 billion in industry clawbacks per payment year, and UnitedHealth, the largest MA insurer, has not sized its exposure.
SAP's U.S. shares fell from Monday's close of $233.83 to $221.99 by late Tuesday morning in New York, a -5.06% decline recorded during regular trading hours. The company-specific trigger was the announced exit of Chief Customer Officer Thomas Saueressig, an executive board member since 2019, who will leave at the end of March 2027 to become CEO of IONOS; the disclosure came before the U.S. open.
Different growth engines: MRVL is riding accelerating AI data-center demand for custom chips and networking, while QCOM remains heavily tied to a soft smartphone market. Momentum contrast: Marvell's data-center revenue guidance has strengthened, whereas Qualcomm's near-term outlook has been pressured by memory-supply constraints and shrinking handset volumes.
TMC fell from Monday's $2.11 close to $1.96 by 10:10 a.m. ET, a -7.11% decline that occurred entirely in the regular session after an early premarket gain faded. No verified news or fundamental catalyst found for the drop; the move is likely technical, extending the post-Q3 unwind that followed NOAA pushing its certification decision to mid-December, with the stock averaging a 4.0% daily swing and logging 11 sessions of 7%-or-larger moves in the last 60.
IonQ slid from Monday's close of $26.45 to $24.73 on Tuesday, a -6.50% move that unfolded during regular trading hours after modest premarket gains faded. The decline was sector-driven rather than company-specific: quantum and AI-adjacent speculative names extended a multi-session liquidation ahead of Nvidia's quarterly report, with unease over Nvidia's abrupt CEO transition keeping risk appetite weak.